HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


DHA Omega-3 Study Leaves Door Open For Role In Dementia Onset Prevention

This article was originally published in The Tan Sheet

Executive Summary

Researchers conclude DHA fatty acid supplementation does not treat Alzheimer's disease, but they say the omega-3 substance may help prevent the onset of dementia.

You may also be interested in...

DHA Supports Memory In Healthy Adults, Study Says

DHA supplementation may improve early memory and learning deficits associated with cognitive aging in healthy adults, according to a first-of-its-kind study in the November issue of Alzheimer's & Dementia.

NCCAM Strategy Stresses Steps Toward Better Trials For Supplements

The nutritional product industry expects benefits from the National Center for Complementary and Alternative Medicine draft strategic plan's emphasis on funding more preliminary research needed to launch informative clinical trials on supplement ingredients

Abbott's ‘Bedrock Of Good Health’ Nutritionals Business Faces Mounting Infant Formula Litigation

Nutritional product business had 5.1% Q1 sales growth and is like Abbott’s other segments, “super well-aligned to the global demographics and trends in health care,” says CEO Ford. But as it defends complaints of damages from powder formulas made at facility found with unsafe levels of bacterial contaminants, Abbott’s also targeted in litigation alleging failure to warn about risk of infants born prematurely developing necrotizing enterocolitis if fed cow’s milk-based formula.


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts